Navigation Links
Researchers discover link between organ transplantation and increased cancer risk
Date:7/15/2008

PHILADELPHIA Researchers have determined a novel mechanism through which organ transplantation often leads to cancer, and their findings suggest that targeted therapies may reduce or prevent that risk.

In the July 15, 2008, issue of Cancer Research, researchers at Harvard Medical School found in animal and laboratory experiments that the anti-rejection, immunosuppressive drug cyclosporine ramps up expression of vascular endothelial growth factor (VEGF), which signals the growth of new blood vessels that can feed tumors.

They also found that simultaneously administering an anti-VEGF therapy with cyclosporine in mice repressed this tumor growth. Several inhibitors of VEGF are already in use in human cancer therapy.

The findings could offer some good news for the 15 to 20 percent of transplant patients who develop cancer within a decade of receiving new organs, according to the study's senior investigator, Soumitro Pal, Ph.D., an assistant professor at Harvard Medical School's Transplantation Research Center at Children's Hospital in Boston.

"It may be that anti-VEGF agents given judiciously after transplantation can reduce future cancer occurrence," he said.

VEGF expression is markedly increased in patients post-transplantation, and this can aid in the development of a blood supply to a transplanted organ, helping it survive and thrive. "But once the organ has stabilized, it may be possible to lower the level of VEGF expression to prevent tumor growth," he said. "We would need to figure out how to balance benefit and risk to keep cancer at bay."

Tumors that develop after transplantation may have three potential sources: they may have pre-existed or could have been a recurrence of previous cancer and in both of these cases, a patient's pre-transplant immune system might have kept these cancers in check or cancer-causing viruses could have come from the donor organ. Physicians have long observed that immunosuppressive agents, such as the class of calcineurin inhibitors that includes cyclosporine, appear to promote cancer development, often in organs that are not transplanted, but the cause of this was unclear. The Harvard team tested the ability of cyclosporine to promote growth of pre-existing tumors in mice implanted with human renal (kidney) cancer cells. Mice treated with the agent formed tumors faster than untreated mice, but anti-VEGF therapy substantially reduced that excessive growth.

Digging deeper into the biological pathway of VEGF activation, the scientists found that cyclosporine activates two of the three forms of the common protein catalyst, protein kinase C, which leads to increased expression of VEGF.

"We think PKC-mediated VEGF transcriptional activation is a key component in the progression of cyclosporine-induced post-transplantation cancer," Pal said. "It is likely not the whole story, but this gives us a clue that we might be able to use existing or novel therapies to reduce cancer risk in transplanted patients."


'/>"/>

Contact: Jeremy Moore
Jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. Dartmouth researchers discover gene signatures for scleroderma
2. Louisiana Tech researchers feature drug reformulation in prestigious journal
3. UCLA researchers locate and image prostate cancer as it spreads to lymph nodes
4. Researchers catch ion channels in their opening act
5. UGA researchers discover mechanism that explains how cancer enzyme winds up on ends of chromosomes
6. Researchers hack final part of the immune system code
7. Iowa State researchers study ground cover to reduce impact of biomass harvest
8. From foe to friend: Researchers use salmonella as a way to administer vaccines in the body
9. Researchers reveal types of genes necessary for brain development
10. Researchers identify cancer preventive properties in common vitamin supplement
11. UT Southwestern researchers identify new targets for RNAs that regulate genes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
(Date:3/24/2017)... 2017 The Controller General of Immigration from Maldives ... Algeen have received the prestigious international IAIR Award for the most ... Reading ... Maldives ... Abdulla Algeen (small picture on the right) have received the IAIR award ...
Breaking Biology News(10 mins):
(Date:7/20/2017)... ... July 20, 2017 , ... The ... the Elihu Thomson Professor of Electrical Engineering and Computer Science at the Massachusetts ... Presented annually, the award recognizes an individual who has made and is continuing ...
(Date:7/20/2017)... ... July 20, 2017 , ... Corista, a leader in ... intelligence Tuesday, July 25, during the Association of Pathology Chairs’ Jubilee Meeting in ... , Baras, Associate Director of Pathology Informatics, will present “The Digital Pathology Experience ...
(Date:7/18/2017)... ... 18, 2017 , ... Sourcing custom glass or quartz parts can be a ... to properly execute your job can take many hours of emails, phone calls and ... designed to showcase the company’s capabilities and core custom categories, and enables you to ...
(Date:7/18/2017)... ... July 18, 2017 , ... ... Software ( https://dataformsoftware.com ) announces the migration of its flagship cloud-based product Planet ... is a team-centric, enterprise work management system that merges strategic and financial planning ...
Breaking Biology Technology: